: Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib may act through off-target effects. However, we found that low-dose of ALK inhibitors, crizotinib and ceritinib, may stimulate ICD in anaplastic large cell lymphoma, in which ALK is activated due to a chromosomal translocation, suggesting on target ICD-promoting effects.
Crizotinib and ceritinib trigger immunogenic cell death via on-target effects / Petrazzuolo, A.; Perez-Lanzon, M.; Liu, P.; Maiuri, M. C.; Kroemer, G.. - In: ONCOIMMUNOLOGY. - ISSN 2162-402X. - 10:1(2021), p. 1973197. [10.1080/2162402X.2021.1973197]
Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
Maiuri M. C.;
2021
Abstract
: Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib may act through off-target effects. However, we found that low-dose of ALK inhibitors, crizotinib and ceritinib, may stimulate ICD in anaplastic large cell lymphoma, in which ALK is activated due to a chromosomal translocation, suggesting on target ICD-promoting effects.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.